Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT06537310
Active, not recruiting Phase 1

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT06537310 · tracked via the Priya Life Science Spain tracker
Sponsor
Hoffmann-La Roche
Phase
Phase 1
Started
2024-09-16
Last updated
2026-10-01

Condition(s) studied

Cancer-Neoplasms

Investigational drug(s) / intervention(s)

RO7567132 and AtezolizumabRO7567132 and Atezolizumab

RO7567132 and Atezolizumab: RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.

RO7567132 and Atezolizumab: RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female participants aged ≥18 years * Body weight \> 40 kilograms (kg) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 and Life expectancy of at least 12 weeks * Participants with advanced and/or metastatic solid tumors * Availability and willingness to provide a mandatory archival tumor specimen or (if not available) a fresh baseline biopsy * Negative serum pregnancy test * Participants must have adequate cardiovascular, hematological, liver and renal function. Exclusion Criteria: * Known central nervous system (CNS) tumors or metastases and leptomeningeal metastases * Active second malignancy within 2 years prior to screening * History or current clinically significant cardiovascular/cerebrovascular disease * Active or history of autoimmune disease * Serious, uncontrolled infection * Known clinically significant liver disease * Unresolved acute toxicity \> grade 1 from prior therapy

Primary outcome measure(s)

  • Percentage of Participants with Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0) — Up to a maximum of 27 months
  • Percentage of Participants With Dose-limiting Toxicities (DLTs) — From baseline to 3 weeks on study

Trial sites (11)

FacilityCityRegionStatus
Kinghorn Cancer Centre Darlinghurst New South Wales
Austin Health Heidelberg Victoria
UZ Leuven Gasthuisberg Leuven Belgium
BC Cancer ? Vancouver Vancouver British Columbia
Princess Margaret Cancer Center Toronto Ontario
McGill University Health Center Montreal Quebec
Rigshospitalet København Ø Denmark
Clinica Universidad de Navarra Pamplona Navarre
Vall d?Hebron Institute of Oncology (VHIO), Barcelona Barcelona Spain
Clinica Universidad de Navarra Madrid Madrid Spain
Fundacion Jimenez Diaz Madrid Spain

More Hoffmann-La Roche trials in Spain

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Recruiting
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) Active, not recruiting
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus Active, not recruiting
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Active, not recruiting

Other trials for the same condition

Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06537310 on ClinicalTrials.gov ↗ ← All trials in Spain